MicroPort® EP Represented in the 19th International Forum on Atrial Fibrillation

Dalian, China, 21 July 2021 — Shanghai MicroPort EP MedTech Co., Ltd. (MicroPort® EP) was recently represented at the 19th International Forum on Atrial Fibrillation (CAFS 2021). The forum, themed, “New Concept, New Approach, New Future”, looked at key milestones in the field of treatments for atrial fibrillation over the past 20 years, whilst also looking towards future development in the field. During the Forum, MicroPort® EP attracted wide attention from practitioners through presentations and demonstrations of its Columbus®️ 3D EP Navigation System V3, which features electromagnetic positioning.

MicroPort® EP also held a satellite session entitled, “Strengthening Chinese brands: AF diagnosis and treatment supported by MicroPort® EP”. This session involved an exchange of case studies, experience in the use of consumables, procedures, and the application of electrophysiological devices in the context of China’s medical insurance system. The efforts of MicroPort® EP were recognized by experts in attendance, including Professor Fengmin Lu from the Tianjin Chest Hospital who noted that he was “pleased to see the advances and innovation of Chinese medical devices.”

Professor Shaolong Li from the Yan'an Hospital affiliated to Kunming Medical University, gave a detailed introduction to the relationship between the aortic sinus and the left and right atria through a case study of ablation of focal atrial tachycardia from the non-coronary aortic sinus, which was guided by the Columbus®️ 3D EP Navigation System. Using the Columbus® system to map the internal structures, he completed the ablation in less than 40 minutes.

Similarly, other experienced physicians made presentations on their experiences with MicroPort® EP's products, including Professor Guojian Sun from the Zhejiang Greentown International Cardiovascular Hospital, who presented his experience with the use of MicroPort® EP's Steerable Introducer in atrial fibrillation cases. Professor Guojian Sun stated his belief that “the clinical experience of MicroPort® EP’s Steerable Introducer is comparable to that of imported devices both in vitro and in vivo”.

As the leading electrophysiological medical device company in China, MicroPort® EP is committed to providing quality and affordable products and services. In the future, MicroPort® EP will continue to devote itself to the field of cardiac arrhythmias, provide more electrophysiologists around the world with easy and safe diagnostic devices, and enable more patients with cardiac arrhythmias to receive more effective treatment and enjoy a healthier life.

About MicroPort® EP

Shanghai MicroPort EP MedTech Co., Ltd, a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), was established in the Shanghai International Medical Zone on August 31, 2010. Its concentration is on the development, manufacture, and marketing of minimally invasive medical devices for the treatment of electrophysiological diseases, including cardiac ablation catheters, diagnostic catheters, 3D navigation systems, amongst others.